羟基红花黄色素A注射剂、阿司匹林及波立维对家兔血小板聚集及超微结构的影响被引量：1

The effects of HSYA injection,aspirin and clopidogrel on platelet aggregation and ultrastructure in rabbits

下载PDF

导出

摘要目的:观察羟基红花黄色素A(HSYA)注射剂、阿司匹林和波立维对家兔血小板聚集功能及超微结构的影响。方法:采用体内实验法,观察羟基红花黄色素A注射剂、阿司匹林和波立维对由花生四烯酸(AA)、二磷酸腺苷(ADP)和血小板活化因子(PAF)诱导的家兔血小板聚集作用的影响,以及血小板超微结构的变化。结果:羟基红花黄色素A注射剂能抑制AA、PAF诱导的家兔血小板聚集;扫描电镜显示:羟基红花黄色素A注射剂能减少AA和PAF诱导后的聚集型血小板数量并使树突型血小板突起变少变短。结论:羟基红花黄色素A注射剂具有抗PAF诱导的血小板聚集作用,抑制血小板的活化,从而为临床抗血小板聚集药物的使用提供更多选择。 Objective： To observe the effects of HSYA injection, aspirin and clopidogrel on platelet aggregation and ultrastructttre in rabbits. Methods： In vivo experiments, when arachidonic acid { AA）, adenosine diphosphate （ADP} and platelet activating factor （PAF} induced respectively, we observed the impacts of HSYA injection, aspirin and clopidogrel on platelet aggregation and ultrastructural changes of platelets. Results： HSYA injection inhibited AA and PAF - induced platelet aggregation. Scanning electron microscope showed： HSYA injection could reduce the number of aggregation type plateles which were induced by AA and PAF; and make fewer and shorter processes of dendritic platelets. Conclusion： HSYA injection can antagonism PAF- induced platelet aggregation and inhibit the activation of platelets. Thus for, there will be more choices for clinical using of anti - platelet aggregation drugs.

作者徐露董志黄彦

机构地区重庆医科大学药学院重庆市中医院研究部

出处《激光杂志》 CAS CSCD 北大核心 2012年第4期73-75,共3页 Laser Journal

关键词羟基红花黄色素A 血小板电镜 PAF HSYA platelets electron microscopy PAF

分类号 TN474 [电子电信—微电子学与固体电子学]

引文网络
相关文献

参考文献6

1黄继汉,黄晓晖,陈志扬,郑青山,孙瑞元.药理试验中动物间和动物与人体间的等效剂量换算[J].中国临床药理学与治疗学,2004,9(9):1069-1072. 被引量：1385
2STARITZ P, KURZ K, STOLL M, et al. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2YI2- ADP tecepter gene[ J ]. International Journal of Cardiology, 2009,133:341 - 345.
3ZIMMERMAN G A, WEYRICH A S. Signal - dependent protein synthesis by activate platelets: new pathway to altered phenotype and function[ J]. Arteriosclerosis, Thrombosis and Vasular Biology, 2008, 28:17.
4吴小平,刘放.抗血小板聚集药物研究进展[J].浙江省医学科学院学报,2009(2):38-42. 被引量：3
5郭晖,刘媛,胡玉龙.抗血小板药物研究进展[J].中国药物与临床,2007,7(9):694-695. 被引量：12
6Hankey GJ, Eikelboom JW. Aspirin resistanee[ J]. Lancet, 2006, 367 (9510) :606 - 617.

二级参考文献13

1规范应用阿司匹林治疗缺血性脑血管病的专家共识[J].中华内科杂志,2006,45(1):81-82. 被引量：76
2[4]ww.fda.gov/cder/cancer/animalframe.htm
3[5]FDA Guidance for industry and reviewers: Estimating the safe starting dose in clinical trials for therapeutics in adult healthy volunteers[ S]. 2002; 12
4[6]FDA Guidance for Industry: food-effect bioavailability and fed bioequivalence studies[ S]. 2002; 12
5O'Brien JR. Effects of salicylates on human platelets. Lancet, 1968,1 : 779-783.
6Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971,6(9) :231-235.
7Diener HC, Cunha L, Forbes C, et al. European stroke prevention study 2: dipyfidamole and acelylsalicylic acid in the secondary prevention of stroke. J Neurol SCI, 1996,143(1-2): 1- 13.
8Savcic M, Hauert J, Bachmann F, et al. Clopidogrel loading dose regimes: kinetic profile of pharmacodynamic responses in healthy subjects. Semin Thromb Haemost, 1999,25Suppl 2:15- 19.
9Helft G, Osende JI, Worthley SG, et al. Acute antithrombotic effect of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol, 2000,20( 10): 2316-2321.
10Patrono C, Coller B, Fitzgerald GA, et al. Platelet-active drugs the relationships among dose, effctiveness, and side effects: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 2004,126: 234S-264S.